Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

Autor: Saad, Fred, Fizazi, Karim, Jinga, Viorel, Efstathiou, Eleni, Fong, Peter C, Hart, Lowell L, Jones, Robert, McDermott, Raymond, Wirth, Manfred, Suzuki, Kazuhiro, MacLean, David B, Wang, Ling, Akaza, Hideyuki, Nelson, Joel, Scher, Howard I, Dreicer, Robert, Webb, Iain J, de Wit, Ronald
Zdroj: In The Lancet Oncology March 2015 16(3):338-348
Databáze: ScienceDirect